期刊文献+

HPLC测定磷酸奥司他韦原料药的含量并检测其有关物质 被引量:6

Determination of Oseltamivir phosphate and its related substances by HPLC
原文传递
导出
摘要 目的建立测定磷酸奥司他韦原料药含量及其有关物质的方法。方法采用HPLC法,用LunaC8柱,流动相为0.05mol·L-1磷酸二氢钾溶液-乙腈-甲醇(620:245:135),流速为1.2mL·min-1,柱温为50℃,检测波长为207nm。结果主峰能与相邻杂质峰较好地分离,磷酸奥司他韦809~1315μg·mL-1的线性关系良好(r=0.9999),平均回收率为100.3%(n=9)。结论所建方法简便、准确、专属性好,可用于磷酸奥司他韦原料药的含量及其有关物质的测定。 OBJECTIVE To establish an HPLC method for the determination of Oseltamivir phosphate and its related substances. METHODS The chromatographic determination of Oseltamivir phosphate was operated on Luna Cs column with a flow rate of 1.2 mL·min^-1 of the mobile phase consisting of phosphate buffer ( 0.05 mol·L^-1 potassiam dihydrogen phosphate) - acetonitrile - methanol(620 : 245 : 135 ). The detection wavelength was set at 207 nm, and the column oven was maintained at 50℃. RESULTS Osehamivir phosphate was completely separated from impurities. The calibrated linear curve of Osehamivir phosphate was within 809 - 1315 μg·mL^-1(r =0.9999),the average recovery was 100.3% (n = 9). CONCLUSION A simple, rapid and sensitive HPLC method for determination of Osehamivir phosphate and its related substances was established.
出处 《华西药学杂志》 CAS CSCD 北大核心 2009年第6期637-639,共3页 West China Journal of Pharmaceutical Sciences
关键词 磷酸奥司他韦 高效液相色谱法 有关物质 含量测定 Osehamivir phosphate HPLC Related substances Determination
  • 相关文献

参考文献5

  • 1Hayden FG,Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza randomized controlled trials for prevention and treatment [ J ]. JAMA, 1999,282 : 1240 - 1246.
  • 2Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor Osehamivir in treating acute influenza[J]. JAMA, 2000, 283:1016 - 1024.
  • 3王孟昭,孙武装,王亚梅,李龙芸,蔡伯蔷,朱华栋,于学忠,朱元珏.磷酸奥司他韦治疗流行性感冒的临床疗效和安全性[J].中华传染病杂志,2003,21(2):114-117. 被引量:35
  • 4陈晓红,祝亚非,关山越,姚骏骅,任三香,张倩芝.抗流感药物奥司他韦的结构确证[J].广州化工,2006,34(6):34-35. 被引量:2
  • 5中华人民共和国国家药典委员会.中国药典[S].二部.北京:化学工业出版社,2005.303.附录 14.

二级参考文献9

  • 1陈晓红,张卫红,张倩芝,陈建.抗流感药物磷酸奥斯他韦的分子振动光谱研究[J].分析测试学报,2006,25(z1):47-48. 被引量:1
  • 2[1]Laver G,Garman E.[J] Science,2001,293(5536):1776~1777.
  • 3[2]Kim C U,Lew W,Williams M A,et al,[J] J Am Chen Soc,1997,119(4)681-690.
  • 4Kim CU, Lew W, Williams MA, et al. Influenza neuraminidasc inhibitors possessing a novel hydrophobic interaction in the enzyme active site. J Am Chem Soc, 1997,119:681-690.
  • 5Hayden FG, Treanor J J, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza:randomized eontrolled trials for prevention and treatment. JAMA,1999,282 : 1240 -1246.
  • 6Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med, 1999,341 : 1336-1343.
  • 7Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA, 2000, 283:1016-1024.
  • 8Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficicy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet, 2000,355:1845-1850.
  • 9Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis, 1999,180:254-261.

共引文献65

同被引文献62

  • 1甲型H1N1流感诊疗方案(2009年试行版第一版)[J].中国继续医学教育,2009,1(2):51-53. 被引量:3
  • 2王玉,李忠红,张正行,安登魁.拉曼光谱在药物分析中的应用[J].药学学报,2004,39(9):764-768. 被引量:41
  • 3陈明泉,施光峰,李谦,胡越凯,秦刚.磷酸奥司他韦治疗流行性感冒疑似患者的临床研究[J].现代诊断与治疗,2005,16(4):197-200. 被引量:10
  • 4王浩宇.磷酸奥司他韦治疗流行性感冒的研究进展[J].实用医技杂志,2006,13(23):4167-4168. 被引量:1
  • 5http://www, moh. gov. cn/publicfiles/business/htmlfiles/H1N1/s10621/ 201001/45546. htm.
  • 6Laborde - Kummer E, Gaudin K, Joseph - Charles J, et al. Development and validation of a rapid capillary electrophoresis method for the determination of oseltamivir phosphate in Tamiflu and generic versions [J].J Pharm Biomed Anal, 2009, 50(3): 544.
  • 7Lindeg ardh N, Hien TT, Farrar J, et al. A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu [ J ]. J Pharm Biomed Anal. 2006, 42 (2) : 430.
  • 8Sweeny DJ, Lynch G, Bidgood AM, et al. Metabolism of the Influenza Neuraminidase Inhibitor Prodrug Osehamivir in the Rat [ J ]. Drug Metab Dispos, 2000, 28(7): 737.
  • 9Wiltshire H, Wiltshire B, Citron A, et al. Development of a high - performance liquid chromatographic - mass spectrometric assay for the specific and sensitive quantification of Ro 64 - 0802, an anti - influenza drug, and its pro - drug, oseltamivir, in human and animal plasma and urine [ J ]. J Chromatogr B, 2000, 745 (2) : 373.
  • 10Lindegardh N, Hanpithakpong W, Wattanagoon Y, et al. Development and validation of a liquid chromatographic - tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine [ J ]. J Chromatogr B, 2007, 859(1) : 74.

引证文献6

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部